Anna Nijdam Sells 1,829 Shares of Pharvaris (NASDAQ:PHVS) Stock

by · The Cerbat Gem

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) insider Anna Nijdam sold 1,829 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.60, for a total value of $55,967.40. Following the completion of the sale, the insider owned 48,945 shares of the company’s stock, valued at $1,497,717. This represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

  • On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The stock was sold at an average price of $30.74, for a total value of $169,100.74.

Pharvaris Stock Up 0.7%

Shares of NASDAQ PHVS traded up $0.20 during mid-day trading on Tuesday, reaching $29.88. 191,721 shares of the company were exchanged, compared to its average volume of 227,155. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -9.40 and a beta of -2.34. Pharvaris N.V. has a 1 year low of $15.46 and a 1 year high of $33.33. The firm has a 50-day moving average of $28.52 and a 200 day moving average of $26.90.

Pharvaris (NASDAQ:PHVS – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. On average, equities analysts forecast that Pharvaris N.V. will post -3.25 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares during the period. JPMorgan Chase & Co. grew its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. Legal & General Group Plc grew its holdings in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the period. Amundi grew its holdings in Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after purchasing an additional 7,879 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Citizens Jmp decreased their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Finally, Wolfe Research initiated coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price on the stock. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $49.18.

Get Our Latest Stock Analysis on Pharvaris

About Pharvaris

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Recommended Stories